- Market Capitalization, $K 168,116
- Shares Outstanding, K 22,780
- Annual Sales, $ 0 K
- Annual Income, $ -129,070 K
- 60-Month Beta 1.28
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 2.97
|Period||Period Low||Period High||Performance|
| || |
+2.24 (+43.75%)since 06/14/19
| || |
-1.12 (-13.21%)since 04/15/19
| || |
-14.00 (-65.54%)since 07/13/18
Axovant (AXGT) closed the most recent trading day at $7.38, moving +0.68% from the previous trading session.
As of late, it has definitely been a great time to be an investor Axovant Sciences.
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.
Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.
Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.
bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype....
Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.
Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.
Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.